First American Bank Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• First American Bank has reduced its holdings in Thermo Fisher Scientific Inc. by 23.4%, selling 6,925 shares to own a total of 22,682 shares valued at approximately $9.2 million.
• CEO Marc N. Casper sold 10,000 shares at an average price of $500.96, resulting in a total transaction of over $5 million, which represents a 7.99% decrease in his stock ownership.
• Despite recent insider sales, the stock holds a consensus rating of "Moderate Buy" among analysts with a price target averaging around $588.35.

First American Bank reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 23.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,682 shares of the medical research company's stock after selling 6,925 shares during the period. First American Bank's holdings in Thermo Fisher Scientific were worth $9,197,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares during the last quarter. Nuveen LLC purchased a new stake in Thermo Fisher Scientific in the first quarter valued at $532,360,000. Sarasin & Partners LLP purchased a new stake in Thermo Fisher Scientific in the first quarter valued at $242,991,000. EdgePoint Investment Group Inc. purchased a new stake in Thermo Fisher Scientific in the first quarter valued at $172,139,000. Finally, Cohen Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 6,655.5% in the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after acquiring an additional 331,180 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 1.1%

NYSE TMO opened at $464.18 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm's fifty day moving average is $476.70 and its two-hundred day moving average is $448.02. The firm has a market cap of $175.28 billion, a PE ratio of 26.85, a P/E/G ratio of 2.49 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the business posted $5.37 earnings per share. The business's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Finally, HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.